eFFECTOR Therapeutics, Inc. (EFTR) Cash Flow Statement
Where EFTR’s cash came from and went, 2023
December 31, 2023 · U.S. dollars- Cash from operations
- −$29.6M
- Capital expenditures
- $97,000
- Free cash flow
- −$29.6M
- Returned to shareholders
- —
- Change in cash
- $6.2M cash at year-end $14.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
EFTR operating cash flow, capex and free cash flow
EFTR cash flow trends, 2019–2023
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$27.6M2019 | −$29.6M2023 | — | |
| Capital expenditures | $4,0002019 | $97,0002023 | +121.9%/yr | |
| Free cash flow | −$27.6M2019 | −$29.6M2023 | — | |
| Free cash flow margin | 32.6%2020 | −734.3%2022 | −766.9 pts | |
| Operating cash flow / net income | 0.972020 | −1.582021 | −2.55 | |
| Stock-based compensation | $646,0002019 | $4.6M2023 | +63.3%/yr | |
| Share buybacks (net) | $86,0002019 | $02021 | −100.0% | |
| Capex / revenue | 0.4%2020 | 5.4%2022 | +5.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EFTR cash flow by activity
EFTR net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
EFTR cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$35.8M | −$22.7M | $15.8M | $14.2M | −$29.7M |
| Depreciation & amortization | $111,000 | $53,000 | $24,000 | $160,000 | $307,000 |
| Stock-based compensation | $4.6M | $5.3M | $8.7M | $499,000 | $646,000 |
| Change in working capital | $1.7M | $2.7M | −$238,000 | −$824,000 | $1.1M |
| Other non-cash items | −$130,000 | −$11.3M | −$49.1M | −$211,000 | $117,000 |
| Cash from operating activities | −$29.6M | −$25.9M | −$24.9M | $13.8M | −$27.6M |
| Investing activities | |||||
| Capital expenditures | −$97,000 | −$192,000 | −$42,000 | −$154,000 | −$4,000 |
| Investments (net) | $9.2M | −$17.9M | $565,000 | −$154,000 | −$17.7M |
| Acquisitions & other investing | $5.4M | $192,000 | $42,000 | $154,000 | $17.8M |
| Cash from investing activities | $14.5M | −$17.9M | $565,000 | −$154,000 | $84,000 |
| Financing activities | |||||
| Share repurchases & issuance (net) | — | — | $56,000 | — | −$86,000 |
| Net borrowing (repayment) | — | $0 | $19.8M | −$2.0M | −$2.0M |
| Shares issued | $15.0M | $2.8M | $0 | $0 | $0 |
| Other financing | $6.2M | −$34,000 | $38.9M | $108,000 | $22.3M |
| Cash from financing activities | $21.2M | $2.8M | $58.8M | −$1.9M | $20.2M |
| Summary | |||||
| Net change in cash | $6.2M | −$41.0M | $34.5M | $11.8M | $3.4M |
| Cash at end of period | $14.9M | $8.7M | $49.7M | $15.2M | $3.4M |
| Free cash flow | −$29.6M | −$26.1M | −$24.9M | $13.7M | −$27.6M |
| Free cash flow margin | — | −734.3% | −1,743.4% | 32.6% | — |
| Capex / revenue | — | 5.4% | 2.9% | 0.4% | — |
| Operating cash flow / net income | — | — | −1.58 | 0.97 | — |
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$8.8M | −$9.1M | −$8.3M | −$8.4M | −$10.0M | −$9.3M | −$9.6M | −$6.9M | $3.1M | $19.0M | $8.9M | −$5.5M |
| Depreciation & amortization | $28,000 | $30,000 | $26,000 | $27,000 | $28,000 | $27,000 | $18,000 | $3,000 | $5,000 | $5,000 | $6,000 | $6,000 |
| Stock-based compensation | $1.0M | $1.1M | $1.1M | $1.2M | $1.2M | $1.4M | $1.6M | $1.2M | $1.1M | $5.9M | $2.4M | $161,000 |
| Change in working capital | $479,000 | $2.4M | −$521,000 | −$1.4M | $1.2M | $1.1M | −$141,000 | $2.5M | −$780,000 | $1.9M | −$2.4M | −$553,000 |
| Other non-cash items | $39,000 | −$19,000 | −$99,000 | $15,000 | −$28,000 | −$59,000 | −$71,000 | −$1.2M | −$9.9M | −$31.8M | −$18.0M | $118,000 |
| Cash from operating activities | −$7.3M | −$5.6M | −$7.8M | −$8.6M | −$7.6M | −$6.8M | −$8.2M | −$4.4M | −$6.5M | −$5.0M | −$9.1M | −$5.8M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$54,000 | −$2,000 | −$28,000 | −$13,000 | −$13,000 | −$45,000 | −$77,000 | −$57,000 | −$36,000 | −$6,000 | −$5 |
| Investments (net) | −$6.3M | $8.9M | −$1.9M | −$1.6M | $9.0M | $3.6M | $3.6M | $3.2M | −$28.2M | −$36,000 | −$28.2M | −$28.2M |
| Acquisitions & other investing | $0 | $54,000 | $2,000 | $28,000 | $13,000 | $13,000 | $45,000 | $0 | $0 | $36,000 | $28.2M | −$147.4M |
| Cash from investing activities | −$6.3M | $8.9M | −$1.9M | −$1.6M | $9.0M | $3.6M | $3.6M | $3.2M | −$28.3M | −$36,000 | −$6,000 | −$175.6M |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | — | — | −$37,000 | — | — | — | — | — | — |
| Share repurchases & issuance (net) | — | — | — | — | — | −$37,000 | — | −$42,000 | $3,000 | −$22,000 | −$176.9M | $1 |
| Net borrowing (repayment) | −$556,000 | — | — | — | — | — | — | — | −$37,000 | — | $19.9M | $625 |
| Shares issued | $14.8M | $6.1M | $324,000 | $14.5M | $212,000 | $37,000 | $111,000 | $42,000 | $2.8M | $0 | $62,000 | $16,000 |
| Other financing | $1,000 | $0 | $18,000 | $38,000 | $0 | $0 | $0 | −$42,000 | $0 | $0 | $209.9M | −$94,626 |
| Cash from financing activities | $14.2M | $6.1M | $342,000 | $14.6M | $212,000 | −$37,000 | $111,000 | −$42,000 | $2.7M | −$22,000 | $53.0M | −$78,000 |
| Summary | ||||||||||||
| Net change in cash | $633,000 | $9.5M | −$9.3M | $4.4M | $1.6M | −$3.2M | −$4.5M | −$1.3M | −$32.0M | −$5.1M | $43.9M | −$5.9M |
| Cash at end of period | $15.5M | $14.9M | $5.4M | $14.7M | $10.3M | $8.7M | $11.9M | $16.4M | $17.7M | $49.7M | $54.8M | $10.9M |
| Free cash flow | −$7.3M | −$5.6M | −$7.8M | −$8.6M | −$7.7M | −$6.8M | −$8.2M | −$4.5M | −$6.6M | −$5.0M | −$9.1M | −$5.8M |
| Free cash flow margin | — | −3,469.1% | — | — | — | −1,006.4% | −949.1% | −224.5% | — | −352.7% | −2,124.8% | −840.5% |
| Capex / revenue | — | 33.3% | — | — | — | 1.9% | 5.2% | 3.8% | — | 2.5% | 1.4% | 0.0% |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | −2.12 | −0.26 | −1.02 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
EFTR cash generation
In fiscal 2023 (ended December 31, 2023), eFFECTOR Therapeutics generated -$29.6 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$29.6 million. Cash and equivalents rose by $6.2 million over the year.
Related: EFTR income statement, EFTR balance sheet. See the EFTR stock overview for the latest quote and news.
EFTR cash flow FAQ
What is eFFECTOR Therapeutics's free cash flow?
eFFECTOR Therapeutics's free cash flow was -$29.6 million in fiscal 2023: -$29.6 million of operating cash flow minus $0.1 million of capital expenditures It was -$26.1 million a year earlier..
How much cash does eFFECTOR Therapeutics generate from operations?
eFFECTOR Therapeutics generated -$29.6 million of cash from operating activities in fiscal 2023.
How much does eFFECTOR Therapeutics spend on capital expenditures?
eFFECTOR Therapeutics spent $0.1 million on capital expenditures in fiscal 2023, compared with $0.2 million the year before.